References
- Tang AS, Wells GA, Talajic M et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N. Engl. J. Med.363(25), 2385–2395 (2010).
- Cleland JG, Daubert JC, Erdmann E et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N. Engl. J. Med.352(15), 1539–1549 (2005).
- Gras D, Bocker D, Lunati M et al. Implantation of cardiac resynchronization therapy systems in the CARE-HF trial: procedural success rate and safety. Europace9(7), 516–522 (2007).
- Moss AJ, Hall WJ, Cannom DS et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N. Engl. J. Med.361(14), 1329–1338 (2009).
- Linde C, Abraham WT, Gold MR, St. John Sutton M, Ghio S, Daubert C. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J. Am. Coll. Cardiol.52(23), 1834–1843 (2008).
- Dickstein K, Vardas PE, Auricchio A et al. 2010 focused update of ESC guidelines on device therapy in heart failure: an update of the 2008 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Europace12(11), 1526–1536 (2010).
- Zareba W, Klein H, Cygankiewicz I et al. Effectiveness of cardiac resynchronization therapy by QRS morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). Circulation123, 1061–1072 (2011).
- Tomlinson DR, Bashir Y, Betts TR, Rajappan K. Accuracy of manual QRS duration assessment: its importance in patient selection for cardiac resynchronization and implantable cardioverter defibrillator therapy. Europace11(5), 638–642 (2009).
- Surawicz B, Childers R, Deal BJ, Gettes LS. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part III: intraventricular conduction disturbances: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society: endorsed by the International Society for Computerized Electrocardiology. Circulation119(10), e235–e240 (2009).
- Dickstein K, Bogale N, Priori S et al. The European cardiac resynchronization therapy survey. Eur. Heart J.30(20), 2450–2460 (2009).
- Higgins SL, Hummel JD, Niazi IK et al. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J. Am. Coll. Cardiol.42(8), 1454–1459 (2003).
- Auricchio A, Stellbrink C, Butter C et al. Clinical efficacy of cardiac resynchronization therapy using left ventricular pacing in heart failure patients stratified by severity of ventricular conduction delay. J. Am. Coll. Cardiol.42(12), 2109–2116 (2003).
- Abraham WT, Young JB, Leon AR et al. Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter–defibrillator, and mildly symptomatic chronic heart failure. Circulation110(18), 2864–2868 (2004).
- Daubert C, Gold MR, Abraham WT et al. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial. J. Am. Coll. Cardiol.54(20), 1837–1846 (2009).
Website
- US FDA www.fda.gov